The owners of Falck A/S are considering options for their stakes in a possible deal that could value the Danish ambulance and ...

The acquisition will add a late-stage drug candidate with blockbuster potential to Lundbeck’s neuroscience pipeline.

The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain ...

Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...

Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...

Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely ...

Otsuka has quantified the financial impact of caregivers, calculating that people in the U.S. who look after loved ones with ...

(Reuters) -H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ...

H. Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing ...

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

Shares of Longboard Pharmaceuticals Inc. were soaring more than 51% on Monday after the announcement of H. Lundbeck’s $2.6 billion deal to acquire the California-based clinical-stage biopharmaceutical ...